2024
Adherence to a MIND Diet Pattern Is Associated With Better Cognitive Function and Less Peripheral Inflammation in Breast Cancer Survivors
Orchard T, Winschel T, Weinhold K, Melink Z, Aase D, Schnell P, Gorka S, Lustberg M, Williams N. Adherence to a MIND Diet Pattern Is Associated With Better Cognitive Function and Less Peripheral Inflammation in Breast Cancer Survivors. Current Developments In Nutrition 2024, 8: 103175. DOI: 10.1016/j.cdnut.2024.103175.Peer-Reviewed Original ResearchThe survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapyReal‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2Partnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial
Worthen-Chaudhari L, Schnell P, Hackney M, Lustberg M. Partnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial. Frontiers In Psychology 2024, 15: 1383143. PMID: 38962217, PMCID: PMC11220256, DOI: 10.3389/fpsyg.2024.1383143.Peer-Reviewed Original ResearchTherapeutic physical activityHome exercisesPhysical activitySurvivors of breast cancerSurvivors of cancerDance-based interventionsPartner dancePatient-reported outcomesRandomized controlled trialsIntrinsic motivationRandomized-controlled studyIntrinsic Motivation InventorySecondary analysisExerciseHealthy agingSocial danceSelf-determination theorySensorimotor function deficitsControlled clinical trialsDanceBreast cancerInterventionExtrinsic motivationMotivation InventoryNeuropathy diagnosisOutcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageImpact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
Taylor M, Reddy S, Ashok Kumar P, Hariri D, Sokol E, Sivakumar S, Quintanilha J, Pavlick D, Levy M, Ross J, Lustberg M. Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2024, 42: 1092-1092. DOI: 10.1200/jco.2024.42.16_suppl.1092.Peer-Reviewed Original ResearchTriple negative breast cancerComprehensive genomic profilingGenomic alterationsHER2 statusHER2 2Triple negative breast cancer groupGA frequencyReview of pathology specimensHER2 IHC expressionHER2-low statusHER2-low tumorsLack of clinical dataPD-L1 expressionTumor mutational burdenHER2 IHC scoreHER2 2+Negative breast cancerEvaluate genomic alterationsMann-Whitney U testPotential treatment optionStatistically significant differenceHER2 subgroupsPD-L1Immunotherapy biomarkersChi-square testEpisodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors.
Sukumar J, Lustberg M, Stein J, Schnell P, King J, Schimming D, Hatfield R, Quiroga D, Pariser A, Gatti-Mays M, Williams N, Cherian M, Stover D, Wesolowski R, Ramaswamy B, Tripathy D, Basen-Engquist K, Vaughn J, Sardesai S. Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors. Journal Of Clinical Oncology 2024, 42: e22541-e22541. DOI: 10.1200/jco.2024.42.16_suppl.e22541.Peer-Reviewed Original ResearchEpisodic future thinkingBehavioral interventionsBC survivorsCancer survivorsMaladaptive health behaviorsBaseline DDFuture-oriented eventsBreast cancer survivorsImpact cancer survivorsDecreased impulsivityBehavior change methodsFuture thinkingDD ratesLifestyle engagementBehavioral economic principlesImmediate gratificationDigital behavioral interventionsLifestyle counselingHealth behaviorsLifestyle interventionPromote weight lossLinear mixed effects modelsDigital healthNon-metastatic BCAverage adherenceNeurofilament light chains: A biomarker for vincristine-related neuropathy.
McNally G, Xu M, Voorhees T, Baiocchi R, Bond D, Epperla N, Maddocks K, Sawhala Y, Ramaswamy B, Lustberg M. Neurofilament light chains: A biomarker for vincristine-related neuropathy. Journal Of Clinical Oncology 2024, 42: 12114-12114. DOI: 10.1200/jco.2024.42.16_suppl.12114.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPatient-reported outcomesNF-L levelsPeripheral neuropathyTime point 3Cancer Institute Common Terminology Criteria for Adverse EventsNational Cancer Institute Common Terminology Criteria for Adverse EventsCommon Terminology Criteria for Adverse EventsAggressive non-Hodgkin's lymphomaSymptoms of chemotherapy-induced peripheral neuropathyDose-adjusted EPOCHNon-Hodgkin's lymphomaNF-LVincristine-induced neurotoxicityTime pointsLight chainClinician-reported outcome measuresNeurofilament light chainEuropean Organization for Research and TreatmentCycle fourLymphoma treatmentLong-term qualityBlood-based biomarkersChemotherapy typeAdverse eventsSurvivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations.
Hart N, Nekhlyudov L, Smith T, Yee J, Fitch M, Crawford G, Koczwara B, Ashbury F, Lustberg M, Mollica M, Smith A, Jefford M, Chino F, Zon R, Agar M, Chan R. Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations. JCO Oncology Practice 2024, op2300716. PMID: 38684036, DOI: 10.1200/op.23.00716.Peer-Reviewed Original ResearchQuality survivorship careSurvivorship carePractice recommendationsUnmet supportive care needsPalliative care frameworkSupportive care needsSystematic reviewModified Delphi consensus processPerson-centered careEnd of lifeData-driven careMultinational Association for Supportive CareDelphi consensus processSupportive careCancer survivorshipCare goalsIntegrated careCare experiencesCare needsCare frameworkHealth outcomesCommunicating careResourcing carePerson-centeredConsensus processSurvivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations
Hart N, Nekhlyudov L, Smith T, Yee J, Fitch M, Crawford G, Koczwara B, Ashbury F, Lustberg M, Mollica M, Smith A, Jefford M, Chino F, Zon R, Agar M, Chan R. Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations. Supportive Care In Cancer 2024, 32: 313. PMID: 38679639, PMCID: PMC11056340, DOI: 10.1007/s00520-024-08465-8.Peer-Reviewed Original ResearchConceptsQuality survivorship careSurvivorship carePractice recommendationsUnmet supportive care needsPalliative care frameworkSupportive care needsSystematic reviewModified Delphi consensus processEnd-of-lifeResultsA systematic reviewDelphi consensus processMethodsAn expert panelCancer survivorshipCare goalsCancer careCare experiencesCare needsCare frameworkHealth outcomesASCO membersConsensus processCareDelphi studyExpert panelMetastatic cancerA retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, Lustberg M. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter? Leukemia & Lymphoma 2024, 65: 1110-1116. PMID: 38648546, DOI: 10.1080/10428194.2024.2340051.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyIncidence of chemotherapy-induced peripheral neuropathyHIV statusPeripheral neuropathyHIV-associated non-Hodgkin's lymphomaCohort studyDose-adjusted EPOCHNon-Hodgkin's lymphomaLong-term patient outcomesRetrospective cohort studyNon-HodgkinComprehensive cancer centerCancer CenterHIVPatientsNeuropathyPatient outcomesPropensity scoreLymphomaAdverse effectsIncidenceStatusRegimenVincristineLong-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopauseThe Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatmentPromise and Perils of Large Language Models for Cancer Survivorship and Supportive Care
Bitterman D, Downing A, Maués J, Lustberg M. Promise and Perils of Large Language Models for Cancer Survivorship and Supportive Care. Journal Of Clinical Oncology 2024, 42: 1607-1611. PMID: 38452323, PMCID: PMC11095890, DOI: 10.1200/jco.23.02439.Peer-Reviewed Original ResearchRandomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, Tsai N, Synold T, Feng Y, Kalu C, Sedrak M, Yee L. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. Breast Cancer Research And Treatment 2024, 205: 61-73. PMID: 38280052, PMCID: PMC11062803, DOI: 10.1007/s10549-023-07223-4.Peer-Reviewed Original ResearchAI-induced arthralgiaBrief Pain Inventory-Short FormRandomized placebo-controlledPostmenopausal womenPlacebo-controlledBreast cancerDouble-blind pilot trialDouble-blind clinical trialGrip strengthReduced risk of recurrenceDiscontinuation of treatmentRisk of recurrenceGastrointestinal adverse effectsPilot trialPlasma curcuminInflammation-related conditionsPatient-reported outcome measuresSerum estradiolWell-toleratedEstrone levelsPurposeAromatase inhibitorsTreatment armsRandomized trialsT0-T3Study agentsPhase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab.
Noonan A, Schnell P, Trunzo D, Thornton W, Malalur P, Manne A, Abushahin L, Rahman S, Jin N, Hays J, Elkhatib R, Mittra A, Roychowdhury S, Lustberg M, Sparreboom A, Hu S. Phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab. Journal Of Clinical Oncology 2024, 42: 745-745. DOI: 10.1200/jco.2024.42.3_suppl.745.Peer-Reviewed Original ResearchOrganic cation transporter 2Serum biomarkersEfficacy biomarkersRecommended phase 2 doseRandomized phase II studySide effect of oxaliplatinRat dorsal root gangliaEarly study discontinuationMFOLFOX6 + bevacizumabPhase 2 doseStudy of dasatinibGastrointestinal (GI) cancersOxaliplatin-induced neuropathyPhase II studyEffect of oxaliplatinPhase I trialDose-finding studyLow intermittent dosesDorsal root gangliaDisabling side effectsDose of DAddition of DFOLFOX chemotherapyFOLFOX regimenStudy discontinuationFeasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
Buga A, Harper D, Sapper T, Hyde P, Fell B, Dickerson R, Stoner J, Kackley M, Crabtree C, Decker D, Robinson B, Krystal G, Binzel K, Lustberg M, Volek J. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLOS ONE 2024, 19: e0296523. PMID: 38166036, PMCID: PMC10760925, DOI: 10.1371/journal.pone.0296523.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerStage IV metastatic breast cancerKetogenic dietInsulin resistanceNutritional ketosisPlasma insulinBreast cancerBody compositionAdjuvant therapeutic interventionsMetabolic outcomesCancer patientsPlasma glucoseMetabolic effectsBody fatShort-term studiesBody weightPleiotropic mechanismsTherapeutic interventionsConsistent bloodPhase IMonthsWomenCancerAd libitumChemotherapyAn Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control 2024, 31: 10732748241250189. PMID: 38797949, PMCID: PMC11129578, DOI: 10.1177/10732748241250189.Peer-Reviewed Original ResearchConceptsMetastatic HER2+ breast cancerHER2+ breast cancerStable diseaseBreast cancerCpG-ODNTrastuzumab treatmentTreated patientsHuman epidermal growth factor receptor 2 (HER2)-positiveToll-like receptor 9 agonistHER2-positive breast cancerWeek 2Immune profile changesPeripheral blood mononuclear cellsAdvanced/metastatic breast cancerVEGF-D levelsOpen-label phaseNK cell populationEfficacy of current treatmentsOpen-label studyAggressive breast cancerBlood mononuclear cellsCompared to baselineMedian PFSMetastatic HER2Monocytic MDSCs
2023
Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases
Upadhyay R, Klamer B, Perlow H, White J, Bazan J, Jhawar S, Blakaj D, Grecula J, Arnett A, Mestres-Villanueva M, Healy E, Thomas E, Chakravarti A, Raval R, Lustberg M, Williams N, Palmer J, Beyer S. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases. Cancers 2023, 16: 137. PMID: 38201564, PMCID: PMC10778270, DOI: 10.3390/cancers16010137.Peer-Reviewed Original ResearchIntracranial progression-free survivalProgression-free survivalBreast cancer patientsBrain metastasesOverall survivalYounger patientsCancer patientsRadiation necrosisOlder womenOlder patientsPositive diseaseSystemic therapyMultivariable analysisTreatment patternsBiopsy-proven breast cancer patientsCox proportional hazards regression methodsIncidence of BMOlder breast cancer patientsSingle-institutional retrospective reviewTreatment-related adverse eventsAge groupsBreast cancer brain metastasesMetastatic breast cancer patientsWorse progression-free survivalProportional hazards regression methodsPatient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptoms